AbbVie acquired Gilgamesh's pipeline drug while FDA leadership shifts weighed on deal-making among major pharmaceutical companies.
5 reports, 4 independent
Updated Aug 27
Gone quiet
Reached 4 outlets in its first 24 hours
- Reports
- 5
- Developments
- 1
- Repetition
- 80%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
AbbVie acquired Gilgamesh's pipeline drug while FDA leadership shifts weighed on deal-making among major pharmaceutical companies.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
AbbVie
pharmaceutical company
- FDA
-
Gilgamesh Pharmaceuticals
American pharmaceutical company
Nothing else this week.
Related events
- Syndax Pharmaceuticals and AbbVie are competing in the healthcare and biopharma sector.
- FDA granted designation for a drug under Gibbs' leadership, involving GSK and Gilead Sciences.
- AbbVie, AstraZeneca, and GSK are major players in global drug development, facing challenges in the drug class and pursuing licensing deals with Chinese biotechs.
- Jazz Pharmaceuticals received FDA approval for a drug following positive clinical trial results.
- GSK and Gilead Sciences received multiple approvals for pipeline products and benchmarked performance against competitors.
Coverage
Newest first; wire copies grouped- ZacksWhat Is the Intent Behind AbbVie's Recent Acquisition Spree? AbbVie ABBV has been on an acquisition spree in the past couple of years to bolster the early-stage pipeline, which should drive long-term
- Pharma VoiceAbbVie dives back into the neuro pool with a $1.2B psychedelics play This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily PharmaVoice ne
- ZacksABBV Buys Rights to Bretisilocin, a Novel Psychedelic for Depression AbbVie ABBV has announced a deal with private neuroscience biotech, Gilgamesh Pharmaceuticals, to acquire the latter’s lead pipeli
- Pharmaceutical TechnologyAbbVie agrees to acquire Gilgamesh’s bretisilocin for $1.2bn AbbVie has signed a definitive agreement to acquire Gilgamesh Pharmaceuticals' lead investigational candidate, bretisilocin, for up to $1.
- BioPharma DiveAbbVie to pay $700M for trispecific drug from Ichnos Glenmark This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive new